Get the Stockscreener App
217.14
2.13%
-4.75
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $217.14, with a volume of 2.10M.
It is down -2.13% in the last 24 hours and down -4.52% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$221.89
Open:
$222.52
24h Volume:
2.10M
Relative Volume:
0.37
Market Cap:
$383.68B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
163.84
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-3.11%
1M Performance:
-4.52%
6M Performance:
+16.51%
1Y Performance:
+26.74%
1-Day Range:
$215.83
$223.03
1-Week Range:
$215.83
$225.12
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
217.09 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,021.58 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.16 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
142.50 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.23 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory - Zacks Investment Research
BMO Capital reiterates Outperform rating on AbbVie stock amid growth By Investing.com - Investing.com UK
AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management - MarketBeat
Why AbbVie Has Committed $100bn to US Medicine Supply Chains - Procurement Magazine
How AbbVie’s $100bn Investment Reshapes Pharma Supply Chains - Supply Chain Digital Magazine
AbbVie’s US$100bn Deal Could Transform US Healthcare Access - Healthcare Digital
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? - Yahoo Finance
Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV - MarketBeat
Retirement Planning Group LLC Buys 6,958 Shares of AbbVie Inc. $ABBV - MarketBeat
Kera Capital Partners Inc. Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie’s Trump Deal Unlocks US$100bn for R&D & Manufacturing - Manufacturing Digital
Robeco Schweiz AG Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services - Med Device Online
AbbVie inks USD 5.6bn global licensing deal with Chinese biotech for cancer therapy - medwatch.com
AbbVie strikes deal with Trump, pledges USD 100bn investment over 10 years - medwatch.com
Trump administration strikes deal with AbbVie to cut costs of certain drugs - KCRA
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign - TradingView — Track All Markets
AbbVie and Trump administration reach agreement on drug prices, tariffs - Daily Herald
AbbVie news: Trump administration strikes deal with North Chicago-based company to cut costs of certain drugs - ABC7 Chicago
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions - TradingView — Track All Markets
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon - TradingView — Track All Markets
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings? - The Globe and Mail
AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie’s $100 Billion Gamble: A Strategic Trade With Washington to Lower Drug Costs - abacusnews.com
AbbVie Secures Tariff Relief Pact - GuruFocus
AbbVie pledges $100B to US production in drug pricing deal with Trump - BioPharma Dive
AbbVie and China’s RemeGen kick off year with $5.6bn oncology deal - BioXconomy
Polaris Capital Management LLC Cuts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions - BioSpace
AbbVie reaches 3-year deal with White House to lower drug prices - MSN
Nordea Investment Management AB Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D - Pharmaceutical Technology
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):